Background {#Sec1}
==========

Sepsis is a systemic multiorgan dysfunction secondary to the dysregulated host response to infection as suggested in the latest definition for sepsis (Sepsis-3.0) and has a strong correlation with intensive care unit (ICU) admission and in-hospital mortality \[[@CR1], [@CR2]\]. The recognition and management of sepsis has become a major issue in critical care medicine.

The alteration of immune function has been considered a key factor in the pathogenesis of sepsis \[[@CR3]\]. The host immune system generates a series of substances such as cytokines in response to an infection or injury. IL-6 is a pro-inflammatory cytokine which is involved in the inflammatory reaction at the early stage of sepsis. It serves as a biomarker of the sepsis, and elevated serum IL-6 level indicates the deterioration of the disease and higher tendency to death \[[@CR4], [@CR5]\]. IL-6 blockade therapy is beneficial to the prognosis of sepsis by blocking systemic inflammatory response \[[@CR6]\].

*IL*-6 gene, located at 7p15.3 is responsible for the regulation of the transcriptional activity during inflammation reaction. The possible association between its − 174 G/C polymorphism (rs1800795) at promoter region and the risk and mortality of sepsis has been widely studied. However, the findings are varied among different studies. *IL-6*-174 C allele is thought to block the norepinephrine-induced transcription factor binding to *IL-6* gene promotor and thus to lower the gene expression, which is favorable for inflammation-related diseases \[[@CR7]\]. A meta-analysis by Chauhan M et al. in 2008 did not support the association between − 174 G/C polymorphism and the risk of sepsis in very low birth weight (VLBW) infants \[[@CR8]\]. After that, a meta-analysis in 2013 demonstrated that *IL-6*-174 G/C polymorphism did not have a link with the risk and mortality of sepsis at any age and ethnicity groups \[[@CR9]\]. In recent years, more studies on this topic have been published. A study found that *IL-6*-174 G allele was associated with early-onset sepsis in Saudi infants \[[@CR10]\]. However, Mao Z et al. and Feng B et al. thought it was *IL-6*-174 C allele rather than G allele that contributed to the risk of sepsis induced by pneumonia \[[@CR11], [@CR12]\]. When it came to the mortality of septic patients, Lorente L et al. discovered better survival of septic patients with CC genotype \[[@CR13]\]. Jimenez-Sousa MA et al. found the possible association between *IL-6*-174 CC genotype and a higher septic shock-related mortality in patients who underwent major surgery \[[@CR14]\]. These studies have controversial findings, which made us curious how they would influence the results if they were included in a new meta-analysis. Thus, an updated meta-analysis was made, which was intended to add valuable information to the future studies.

Methods {#Sec2}
=======

Searching strategy {#Sec3}
------------------

We searched PubMed, Web of Science and China National Knowledge Infrastructure (CNKI) for available studies published before September 2018. The keywords for searching were a combination of "IL-6, interleukin-6, rs1800795, -174G/C, polymorphism, sepsis, septicemia, septic shock". Meanwhile, references of the relevant literature reviews were screened to identify potentially relevant publications.

Criteria for inclusion and exclusion {#Sec4}
------------------------------------

The publications fulfilling the following criteria were included: an original study evaluating the association between *IL-6*-174 G/C polymorphism and the risk and/or mortality of sepsis; objects in each study were from same epoch; including a case group of sepsis; including a control group; including precise sample size of *IL-6*-174 G/C polymorphism of case and control groups which could be directly extracted or calculated according to the information available. Excluded were: repetition of the published studies; a meta-analysis or a review; study with insufficient or incorrect data; study with only G or C allele carriers. The screening process is illustrated in a flow chart (Fig. [1](#Fig1){ref-type="fig"}). All publications were identified by two reviewers independently. If two reviewers had opposite views, a third reviewer would be consulted for a decision.Fig. 1Flow diagram of the study selection process

Quality assessment and data extraction {#Sec5}
--------------------------------------

The quality of included studies was evaluated according to Newcastle-Ottawa Scale (NOS) by two researchers \[[@CR15]\]. Available data were extracted by two authors independently. Disagreements were dealt with by a third reviewer. The following information was extracted from studies: first author, year of publication, country of the study and features of case and control groups such as ethnicity, age group, type of case and controls. Some studies discussed both the risk and mortality of sepsis. In this case, the information was collected respectively.

Statistical analysis {#Sec6}
--------------------

The role of minor allele C in the risk and mortality of sepsis was targeted. Thus an analysis was made using dominant model (GC + CC versus GG), recessive model (CC versus GC + GG), co-dominant model (GC versus GG and CC versus GG) and allelic model (C versus G). While some studies only yielded a sum of number of genotypes, they were enrolled in analyses just under certain genetic models \[[@CR16]--[@CR19]\]. Statistical analysis was conducted on Stata 14.1. Each control group underwent goodness-of-fit χ^2^-test for evaluating Hardy-Weinberg equilibrium (HWE). When *P* \> 0.05, the objects were under Hardy-Weinberg equilibrium and within a same Mendelian population. Homogeneity of the studies was tested. When *P* \< 0.1 or *I*^*2*^ \> 50%, a high level of heterogeneity between studies was envisaged and random-effect model was adopted; when *P* \> 0.1 and *I*^*2*^ \< 50%, there was no significant heterogeneity between studies, and fixed-effect model was used. The effect of *IL-6*-174 G/C on the risk or mortality of sepsis was measured by *P* value, odd ratio (OR) and 95% confidence interval (CI). *P* \< 0.05 was reviewed as statistical significance. In the analysis on sepsis risk, subgroup analyses based on age group, ethnicity, restricted healthy controls were conducted. Subgroup analysis on age and ethnicity in the mortality analysis was also made. If no information of age group was given in a study, we considered it would be as a study on adult. The majority of the nation of study was taken as the ethnicity of the study population in case that it was not specifically mentioned. The objects in three studies were mainly Caucasians, so they were included in the subgroup analysis of the Caucasians as the number of non-Caucasians were very small \[[@CR16], [@CR20], [@CR21]\]. Meanwhile, sensitivity analysis was conducted by repeating analysis after omitting one study each time to estimate the effect of quality of studies on the final result. Publication bias was evaluated by Egger's test. Once *P* \> 0.05 in regression test, no obvious publication bias would exist.

Trial sequential analysis {#Sec7}
-------------------------

Meta-analysis might be affected by type I error due to the increased risk of random error and repeated significance testing. Trial sequential analysis (TSA) was a useful tool to verify the reliability of the results from meta-analysis by estimating the required information size (RIS) (sample size of included studies) and calculating the threshold for statistical significance \[[@CR22]\]. A type I error of 5%, power of 80%, relative risk reduction of 20% were defined and control event proportion was an average of each included study. If the Z-curve crossed RIS line, the result of meta-analysis would be conclusive. If the Z-curve crossed the O'Brien-Fleming boundary or futility boundary, the conclusions could be made even before it crossed the RIS line that *IL-6*-174G/C polymorphism have or did not have a correlation with sepsis, respectively. TSA was conducted in the genetic model with the most included studies. If each genetic model had the same number of included studies, TSA would be conducted in allelic model. Meta-analysis which presented a significant result in the pool analysis was also tested under TSA. TSA was conducted on TSA software 0.9.5.10 Beta.

Results {#Sec8}
=======

Searching results {#Sec9}
-----------------

354 studies were initially acquired from databases and 4 studies were from references of publications. After exclusion of irrelevant studies, review and meta-analysis as well as repetitions, 29 studies were identified for full-text review. 5 studies were further excluded after full-text review because of inadequate data for analysis \[[@CR23]--[@CR27]\]. Eventually, 24 studies fulfilled all criteria for inclusion, including 16 studies on the risk of sepsis, 4 studies on the mortality and 4 studies on both topics \[[@CR10]--[@CR14], [@CR16]--[@CR21], [@CR28]--[@CR40]\]. All included studies had a NOS score ≥ 6 (see Additional file [1](#MOESM1){ref-type="media"}: Table S1). Totally, there were 3282 cases and 4926 controls for the analysis on sepsis risk together with 610 cases and 1856 controls for the analysis on mortality. Main characteristics of all studies included as well as the genotype distributions of *IL-6*-174 G/C polymorphism were shown in Table [1](#Tab1){ref-type="table"}.Table 1Main characteristics of the included studiesFirst authorYearCountryAge groupType of caseType of controlEthnicityCaseControlHWE^a^ in controlGGGCCCGGGCCCSchluter B2002USAAdultSepsis, severe sepsisHealthyCaucasian254624719442YesNon-survivorSurvivor21761186YesHarding D2003UKInfantSepticemiaPreterm infantMainly Caucasian2427^b^3076^b^N/ABalding J2003IrelandAdultMeningococcal sepsisHealthyCaucasian59972712320968YesNon-survivorSurvivor13102468725YesTreszl A2003HungaryNeonateSepsisVLBW^c^ neonateCaucasian1813234297YesBarber RC2004USAAdultSevere sepsisICU patients with no or mild sepsisMixed1719^b^6954^b^N/AAhrens P2004GermanyInfantSepsisVLBW^c^ infantsCaucasian242159717732NoMichalek J2006Czech Republicaged 0--19 yearsSIRS^d^, sepsis, severe sepsis, septic shock and MODS^e^HealthyCaucasian10317248160345139YesMcDaniel DO2006USAnot clear^f^SepsisICU patientsAfrican American16^g^06^g^0N/ACaucasian12^g^313^g^8N/ASipahi T2006Turkeyaged 0--15 yearsSevere sepsisHealthynot clear2614452196NoNon-survivorSurvivor9511793YesBaier RJ2006USAInfantSepsisVLBW^c^ infantAfrican American9418211090YesCaucasian121637163YesNon-survivorSurvivorAfrican American101084172YesCaucasian11111152YesGöpel W2006GermanyInfantSepsisVLBW^c^ infantMainly Caucasian29501812814349YesSabeinikovs O2008LatviaInfantNon-survivorSurvivorCaucasian10211320327YesAbdel-Hady H2009EgyptNeonateSepsisNeonates investigated for neonatal hyperbilirubinemiaCaucasian172611283211YesNon-survivorSurvivor25615215YesSolé-Violán J2010SpainAdultSevere sepsis and septic shockCAP^h^Caucasian1411443639234184YesDavis SM2010USAFemale adultPuerperal group streptococcus sepsisHealthyCaucasian1011221229YesCarregaro F2011BrazilAdultSepsis, severe sepsis and septic shockHealthyMainly Caucasian^i^49399949617YesAccardo Palumbo A2011Italyaged 13--82 yearsSepsisBurned patientnot clear14^g^222^g^4N/AWatanabe E2012USAAdultNon-survivorSurvivorCaucasian11314946245363125YesMartín-Loeches I2012SpainAdultSepsis, severe sepsis and septic shockHealthyCaucasian581516130438413102YesFeng B2015ChinaAdultNon-survivorSurvivorAsian42201139723YesAllam G2015Saudi ArabiaInfantEarly-onset sepsisHealthynot clear392010133223YesLorente L2016SpainAdultNon-survivorSurvivornot clear47363767427YesMao ZR2016ChinaAdultSepsisHealthyAsian563795976637NoJimenez-Sousa MA2017SpainAdultSeptic shockHealthyNot clear939019435113Yes^a^Hardy-Weinberg equilibrium^b^GC and CC^c^very low birth weight^d^systemic inflammatory response syndrome^e^multiple organ disorder syndrome^f^patients in surgery intensive care unit^g^GG and GC^h^community-acquired pneumonia^i^Caucasian ancestry mainly, together with small amount of Asian and African ancestry

The association between *IL-6*-174 G/C polymorphism and the risk of sepsis {#Sec10}
--------------------------------------------------------------------------

The results were shown in Table [2](#Tab2){ref-type="table"}. The analysis resulted in no association between *IL-6*-174 G/C polymorphism and the risk of sepsis concerning the overall population under dominant model, recessive model, codominant model and allelic model (dominant model: *P* = 0.743, OR = 0.965, 95% CI: 0.782--1.192; recessive model: *P* = 0.96, OR = 0.992, 95% CI: 0.726--1.356; codominant model GC vs. GG: *P* = 0.57, OR = 0.950, 95% CI: 0.686--1.435; codominant model CC vs. GG: *P* = 0.966, OR = 0.992, 95% CI: 0.686--1.435; allelic model: *P* = 0.894, OR = 1.014, 95% CI: 0.831--1.236) (Fig. [2](#Fig2){ref-type="fig"}). When limiting control group to healthy ones or Mendelian population, the results remained unchanged. In the subgroup analysis on non-adults, adults and Caucasians, no association between *IL-6*-174 G/C polymorphism and the risk of sepsis was found, neither.Table 2Results of the meta-analysis, heterogeneity test and Egger's testMeta-analysisHeterogeneity testEgger's testno. of studiesOR (95% CI)*P* value*I* ^*2*^*P* value*P* valueThe association between *IL-6* -174G/C polymorphism and the risk of sepsisOverall GC + CC vs GG180.965 (0.782--1.192)0.74372.80%\< 0.0010.694 CC vs. GC + GG180.992 (0.726--1.356)0.9672.90%\< 0.0010.81 GC vs. GG160.950 (0.798--1.133)0.5752.00%0.0080.696 CC vs.GG160.992 (0.686--1.435)0.96677.80%\< 0.0010.989 C vs. G161.014 (0.831--1.236)0.89484.20%\< 0.0010.705Non-adult GC + CC vs GG90.796 (0.522--1.214)0.2978.40%\< 0.0010.754 CC vs. GC + GG80.785 (0.614--1.003)0.05341.50%0.1010.337 GC vs. GG80.879 (0.578--1.336)0.54572.90%0.0010.694 CC vs.GG80.779 (0.427--1.421)0.41569.60%0.0020.38 C vs. G80.896 (0.643--1.248)0.51680.10%\< 0.0010.475Adult GC + CC vs GG91.112 (0.900--1.374)0.32459.20%0.0120.464 CC vs. GC + GG101.080 (0.700--1.666)0.7379.50%\< 0.0010.73 GC vs. GG90.988 (0.874--1.117)0.8510%0.7110.816 CC vs.GG91.208 (0.766--1.905)0.41679.60%\< 0.0010.904 C vs. G91.124 (0.868--1.455)0.37586.40%\< 0.0010.63Caucasian GC + CC vs GG160.857 (0.699--1.050)0.13665.20%\< 0.0010.725 CC vs. GC + GG170.892 (0.771--1.033)0.1276.70%0.3760.712 GC vs. GG150.912 (0.756--1.099)0.33352.50%0.0090.954 CC vs.GG150.853 (0.643--1.132)0.27155.00%0.0050.962 C vs. G150.913 (0.787--1.059)0.22866.20%\< 0.0010.821Healthy control GC + CC vs GG100.919 (0.686--1.232)0.57478.60%\< 0.0010.709 CC vs. GC + GG100.985 (0.623--1.557)0.94984.30%\< 0.0010.979 GC vs. GG100.894 (0.791--1.010)0.07247.30%0.0470.871 CC vs.GG100.896 (0.531--1.511)0.68185.50%\< 0.0010.995 C vs. G100.964 (0.726--1.282)0.80389.30%\< 0.0010.747Mendelian population GC + CC vs GG130,947 (0.768--1.167)0.60766.60%\< 0.0010.701 CC vs. GC + GG130.903 (0.777--1.049)0.10127.7%%0.1650.807 GC vs. GG130.971 (0.805--1.171)0.75853.10%0.0120.645 CC vs.GG130.880 (0.647--1.197)0.41661.50%0.0020.698 C vs. G130.945 (0.806--1.109)0.48971.00%\< 0.0010.81The association between *IL-6* -174G/C polymorphism and the mortality of sepsisOverall GC + CC vs GG101.050 (0.705--1.563)0.81257.90%0.0110.059 CC vs. GC + GG101.299 (0.665--2.538)0.44462.20%0.0050.173 GC vs. GG101.045 (0.709--1.540)0.82551.10%0.0310.143 CC vs.GG101.340 (0.611--2.939)0.46567.00%0.0010.113 C vs. G101.103 (0.795--1.531)0.55869.50%0.0010.134Non-adult GC + CC vs GG41.434 (0.810--2.538)0.2160%0.4490.883 CC vs. GC + GG42.957 (1.442--6.066)0.0030%0.4340.684 GC vs. GG41.098 (0.588--2.050)0.770%0.7460.871 CC vs.GG43.221 (1.431--7.250)0.0053%0.380.872 C vs. G41.631 (1.101--2.416)0.01531.90%0.2210.783Adult GC + CC vs GG61.005 (0.593--1.705)0.98573.10%0.0020.126 CC vs. GC + GG61.204 (0.342--4.236)0.77286.50%\< 0.0010.486 GC vs. GG61.078 (0.639--1.818)0.77870.30%0.0050.127 CC vs.GG60.868 (0.341--2.208)0.76666.60%0.010.302 C vs. G60.940 (0.654--1.352)0.73970.90%0.0040.377Caucasian GC + CC vs GG91.206 (0.723--2.007)0.47465.70%0.0030.094 CC vs. GC + GG91.376 (0.656--2.884)0.39967.90%0.0020.097 GC vs. GG91.143 (0.713--1.834)0.57955.50%0.0210.174 CC vs.GG91.430 (0.598--3.420)0.42271.30%\< 0.0010.071 C vs. G91.180 (0.802--1.737)0.40173.50%\< 0.0010.101Fig. 2Forest plot of the association between *IL-6*-174 G/C polymorphism and the risk of sepsis under dominant model. The horizontal line represents the 95% confidence interval. And its length shows the range of the confidence interval and the size of the square in the middle shows the weight of the study. The diamond (and broken line) represents the overall summary estimate, with confidence interval given by its width. The unbroken vertical line is at the null value (OR = 1.0). CI, confidence interval

The association between *IL-6*-174 G/C polymorphism and the mortality of sepsis {#Sec11}
-------------------------------------------------------------------------------

The results were shown in Table [2](#Tab2){ref-type="table"}. In the analysis of overall population, *IL-6*-174 G/C polymorphism did not appear to be associated with the mortality of sepsis in dominant model (*P* = 0.812, OR = 1.050, 95% CI: 0.705--1.563), recessive model (*P* = 0.444, OR = 1.299, 95% CI: 0.665--1 = 2.538), codominant model (GC vs. GG: *P* = 0.825, OR = 1.045, 95% CI: 0.709--1.540; CC vs. GG: *P* = 0.465, OR = 1.340, 95% CI: 0.611--2.939) and allelic model (*P* = 0.558, OR = 1.103, 95% CI: 0.795--1.531). Subgroup analysis on adults and Caucasians did not show any association between *IL-6*-174 G/C polymorphism and mortality. Nevertheless, subgroup analysis on non-adults manifested that *IL-6*-174 G/C polymorphism was associated with worse survival of septic patients in recessive model (*P* = 0.003, OR = 2.957, 95% CI: 1.442--6.066), co-dominant model (CC vs. GG: *P* = 0.005, OR = 3.221, 95% CI: 1.431--7.250) and allelic model (*P* = 0.015, OR = 1.631, 95% CI: 1.101--2.416).

Publication bias and sensitivity analysis {#Sec12}
-----------------------------------------

No obvious publication bias was found in every section of this meta-analysis in Egger's test. The results and graphs of Egger's tests were shown in Table [2](#Tab2){ref-type="table"} and supplementary figures (see Additional file [2](#MOESM2){ref-type="media"}). The results of sensitivity analysis were shown in Table S2 (see Additional file [1](#MOESM1){ref-type="media"}). The results of meta-analysis on the association between *IL-6*-174 G/C polymorphism and the mortality of non-adult (CC vs. GG and allelic model) were changed after omitting certain studies. Additionally, some relevant studies might influence the results of study were also tested in our analyses. An analysis after omitting two studies including elder children from non-adults group was also made, the results being unchanged \[[@CR32], [@CR33]\] (see Additional file [1](#MOESM1){ref-type="media"}: Table S3). Moreover, an study was included in the meta-analysis by Gao et al. but excluded in our study \[[@CR26]\]. Thus an analysis was carried out and proved that the exclusion of this study did not influence the results of our meta-analysis (see Additional file [1](#MOESM1){ref-type="media"}: Table S4).

Trial sequential analysis {#Sec13}
-------------------------

In the meta-analysis on the risk of sepsis, TSA was conducted on analysis of overall population (dominant model and recessive model), non-adults (dominant model), adults (recessive model), Caucasians (recessive) and analysis involving healthy controls (allelic model) and Mendelian population (allelic model). Z-curves crossed the futility boundary and reached the required sample size in those analysis. The exception was the analysis on non-adult group, where Z-curve crossed neither conventional test boundary nor the futility boundary (Fig. [3](#Fig3){ref-type="fig"}). In the meta-analysis on the mortality of sepsis, TSA was conducted on analysis of overall population (allelic model), non-adults (recessive model, codominant model: CC vs. GG and allelic model), adults (allelic model) and Caucasians (allelic model). Although Z-curves crossed the conventional test boundary in the analyses on non-adults, they did neither cross O'Brien-Fleming boundary nor cross the RIS boundary (see Additional file [2](#MOESM2){ref-type="media"}). Z-curves in other TSAs crossed futility boundary and RIS boundary.Fig. 3TSA of the analysis on the association between *IL-6*-174 G/C polymorphism and the risk of sepsis in non-adults under dominant model. A type I error of 5%, power of 80%, relative risk reduction of 20% were defined and control event proportion was an average of each included study. The vertical red line represents the required information size (sample size). The red curves represent the O'Brien-Fleming boundary and futility boundary. The blue line represents the cumulative Z-curve. RIS, required information size

Discussion {#Sec14}
==========

The association between *IL-6*-174 G/C polymorphism and the risk or mortality of sepsis has been widely studied, and previous meta-analyses have been conducted in 2008 and 2013. Five more studies have been published in recent years. Because of the controversial findings, an updated meta-analysis is necessary to bring some new insights into this topic. This study has the largest sample so far to address this issue. What's more, trial sequential analysis was carried out in order to quantify the statistical reliability of the results. No association between *IL-6*-174 G/C polymorphism and the risk or mortality of sepsis in the overall population was found. This is similar to the finding by Gao et al. \[[@CR9]\]. Heterogeneity in each study might be possible, which could arise from age, ethnicity or type of controls. However, subgroup analyses based on those factors did not present any association, either. Trial sequential analysis revealed that the results were reliable, except for the cases concerning non-adults group.

Located at promotor region of *IL-6* gene, − 174 G/C was found to be associated with the lower serum IL-6 level and lower inflammatory response subsequently \[[@CR12], [@CR27], [@CR41]\]. Some previous studies reported the association between *IL-6*-174G/C polymorphism and the risk and mortality of sepsis \[[@CR10]--[@CR12], [@CR16], [@CR29], [@CR31], [@CR32], [@CR34], [@CR39], [@CR40]\]. However, our results again failed to present any association. The reason could be: Firstly, the incidence and development of sepsis was involved in many factors such as gender, pathogens, gene polymorphism, environment effect and medical procedure. *IL-6*-174 G/C polymorphism might influence the transcriptional activity and lower the inflammatory reaction, it did not get the point that it could influence the development of sepsis nevertheless. Secondly, *IL-6*-174 G/C polymorphism might have an impact on the certain groups of people and pathological states, which were not within the subgroups of this study. Thirdly, *IL-6* had many promotor SNPs such as -597G/A, −572G/C, −373A~n~T~n~ and -174G/C, these polymorphic sites did not regulate the gene function independently \[[@CR42]\]. And the influence of linkage disequilibrium could not be underestimated.

It's noteworthy that C allele was associated with poor outcomes of sepsis in non-adults in recessive model, codominant model (CC vs. GG) and allelic model. However, TSA revealed that this result was not reliable as Z-curve crossed neither the conventional test boundary nor the futility boundary. Although many studies demonstrated C allele led to a lower *IL-6* expression, a study on neonates showed serum IL-6 level was higher in C carriers \[[@CR43]\]. It was also found that IL-6 has an age-associated increase during systemic inflammation so that young persons should have a comparatively low IL-6 level during sepsis \[[@CR44]\]. We hypothesized that higher IL-6 level induced by C allele could be more sensitive in very young persons and lead to aggravation of sepsis. This suggested different pathogenesis between non-adults and adults. It's acknowledged that pediatric sepsis had different definitions, clinical presentations and management from adult sepsis. Maternal status also had an impact on newborns \[[@CR45]\]. Thus the effect of *IL-6*-174 G/C polymorphism on the inflammatory process of non-adults might be promising in further studies.

Most included studies in our analysis were concerned with the Caucasians, rather than the Asians. Previous analysis also present that the frequency of *IL-6* -174G/C polymorphism were rare in Asian population that resided in Korea, Japan and Shandong province and Guangxi province of China \[[@CR23], [@CR24], [@CR46], [@CR47]\]. However, two studies included in our analysis reported possible association between *IL-6* -174G/C polymorphism and the risk of sepsis in the Chinese Han population in Henan province \[[@CR11], [@CR14]\]. This suggested that *IL-6* -174G/C polymorphism was distributed in Asians that resided in certain areas and might have an influence on the pathogenesis of sepsis.

As the types of controls were varied, it was considered that the status of controls could influence the results. In some studies, the case group was not comprised of septic patients only. Being compared to healthy controls and to mendelian population, the association with the risk of sepsis was not found, nevertheless. The case group of one study included a part of patients diagnosed as systemic inflammatory response syndrome (SIRS) or multiple organ disorder syndrome (MODS) \[[@CR32]\]. And control group of one study consisted of ICU patients with no or mild sepsis \[[@CR17]\] Because no exact number of the patients with or without sepsis was available, total group was included in the analysis. However, the results remained unchanged after omitting these studies in sensitivity analysis. In subgroup analysis of non-adults on the risk of sepsis, most of studies discussed age groups defined as infant or neonate. Only two studies addressed children under the age of 19 \[[@CR32], [@CR33]\]. After excluding these two studies including elder children, the results remained unchanged. In addition, one study that were included in the meta-analysis by Gao et al. was not included in ours, which was excluded due to limited information to obtain precise data and extreme small sample size of case group (4 patients with GG or GC genotype) \[[@CR26]\]. And we have proven that the exclusion of this study did not affect the result of study.

Our study has two strengths. Firstly, to avoid our analysis to be biased from publication, database, inclusion criteria and language, strict criteria were laid out for enrolling studies and publications in the Chinese language were also searched. Publication bias was tested in Egger's tests. Secondly, TSA was adopted to test the reliability of results and provide the research field which required more studies.

There were several limitations in this study. First, as the definition for sepsis changed, it was unlikely that the enrolled studies would have same definition because our analysis included studies within a large time range. Second, the majority of the objects studied were Caucasians, more studies were needed to further the study on other ethnicity groups. Third, three studies were not under Hardy-Weinberg equilibrium, although the results were not changed after omitting those studies. In addition, we could not get some details of the objects such as treatment and lifestyle, which prevented us from seeking more factors influencing the results.

Conclusions {#Sec15}
===========

In conclusion, we did not find the evidence of the association between *IL-6*-174 G/C polymorphism and the risk or mortality of sepsis. Trial sequential analysis indicated that large sample size was needed to get a more reliable result for the association between *IL-6*-174 G/C polymorphism and the risk and mortality of sepsis in non-adults. More studies on the molecular mechanism and interactions between SNPs were needed.
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